Factors associated with Anti Drug Ab against TNFi over 2-y in axSpA pts are: ⭐️ 🔼 Disease activity ⭐️Development of adverse events ⭐️Treatment discontinuation Abst #0936 #ACR21 @RheumNow

Physician global score was the strongest predictor of future flares in AS patients with TNFi dose tapering. 29 (27%) flared at 2/3 of standard dose, 21 (20%) at 1/2 dose, 29 (27%) at 1/3 dose and 27 (25%) after discontinuation @RheumNow #ACR21 Abst#0929 https://t.co/pIzLgexe3k https://t.co/UM9cGLiYl7

• Tapering of TNF Inhibitors in Patients with Axial Spondyloartritis – Can Flare …

SKIPPAIN results: Spinal pain response after 8 weeks of SEC showed notable differences between HLA-B27 subgroups. Can subtype pre-determine tx efficacy/response? Abs 0917 #ACR21 #RheumNow @RheumNow https://t.co/FKpCqXpobM https://t.co/WbjjyTIaiG

• Efficacy of Secukinumab and HLA-B27 Subtypes: Results from a Phase IIIb Randomi…

GO-ALIVE study by Prof ADeodhar & grp 🔘IV GOL was shown to be effective across all efficacy outcomes in AS pts w/ early & late dse 🔘⬆proportions of pts w/ early dse achieved BASDAI50 and ASDAS inactive dse Early dx and tx 👉better outcomes @RheumNow #ACR21 #ACRBest abs0912 https://t.co/jwvEn5LdDB

Physician global score only predictor of axSpA flares when tapering TNFi ⭐️Changes in imaging did not predict flare Abs#929 #ACR21 @RheumNow https://t.co/vVn6ARKJu0 https://t.co/FlVtlLmTfl

• Tapering of TNF Inhibitors in Patients with Axial Spondyloartritis – Can Flare …

French real-world AxSpA cohort analysis showed drug retention of SEC & TNFi were similar. In subgroups analyses, age, BASDAI at dx & BMI were similar. Abs 0911 #ACR21 #RheumNow @RheumNow https://t.co/ewtmpxKTNu https://t.co/Yh0nX3x83Z

• Drug Retention of Tumor Necrosis Factors and IL-17 Inhibitors in Axial Spondylo…

Although baseline dz was similar in axSpA males/females, study found male pts had more improvements in ASDAS-CRP, CRP, and PGA than females in 6 years of follow-up. Abs 0620 #ACR21 #RheumNow @RheumNow https://t.co/Qr657YeniA https://t.co/35t4oIUSmS

• Is There a Difference in Disease Activity Between Genders in Axial Spondyloarth…

An ongoing axSpA cohort in Netherlands study assessed the rate of progression of nr-axSpA to AS patients over a 6 y period Every 2 y approximately 10% of patients progressed from nr-axSpA to AS Abst # 0907 #ACR21 @RheumNow https://t.co/gGhhssLS5N

Getting closer to personalised medicine in AS, ECM-mediated biomarkers may help predict response to Adalimumab in AS. The biomarkers C1M, C6M and PRO-C4 were lower in responders to adalimumab treatment after 24 weeks @RheumNow #ACR21 Abst#0915 https://t.co/K2YxPvUAwu https://t.co/w9kcBSFeG9

• Biomarkers of Extracellular Matrix Turnover Reflect Treatment Response and Phar…